Identify a mechanism metabolic in mice that could be key in the treatment of obesity

MADRID, (EUROPA PRESS) Researchers from the University of Texas Southwestern in Dallas (united States) have discovered a mechanism metab’lico in mice that couldíto be a key to the treatment of obesity. The research’n, published in the edition’re a digital magazine ‘Cell Metabolism’ reveals the role of a hormone which promotes a state similar to the hibernaci’re in starving mice. S&number;n the researchers, the hormone called fibroblast growth factor 21 (FGF21) is released in starving mice by a cellular receptor específico that controls the use of fat as energy’.

The liberaci’n of FGF21 triggers a change metab’lico to burn stored fat instead of carbohydrates and induces a state similar to the hibernaci’re in the that decreases the body temperature and the activity física. All these processes have as objective to promote the survival of the animal. For their work, the researchers focused on the study of a nuclear receptor, a proteína that activates and deactivates genes in the body, called receptor-alpha proliferator-the peroxisome, or PPAR-alpha, which is known for its control over the use of fat as energyía. The starving mice without PPAR-alpha become hipoglicémicos and die so ráask. When analyzing the impact molecular of PPAR-alpha in the mice, the researchers discovered that the proteína stimulates the production’n of FGF21, one of the members of the family hormone that decreases glucose levels in obese mice and diabéticos. S&number;n explains Steven Kliewer, senior author of the study, "when provided to mice this hormone, your metabolism behaved as if they were hungry, even afterés that had been eating shortly before". Kliewer está interested in understanding c’mo FGF21 affects processes such as reducci’re the president’n sanguínea, cholesterol, and blood glucose levels, both of which are achieved with a limited intake of food. S&number;n the researcher, given that PPAR-alpha is a receptor used as a target for fármacos that promote the lipoproteínas, high-density, or good cholesterol, and reduces the amount of fat in the blood, this mechanism couldíto lead to a new class of fármacos that affects many human disorders.